The premium is large; the deal is not yet complete

Silence Therapeutics announced on 19 October that Germany's Merck KGaA had agreed to acquire the London-based biotechnology company in an all-cash transaction valuing its equity at approximately $1.3 billion. The price is $20 per American Depositary Share, a 130% premium to Silence's 16 October closing price. The companies put enterprise value at about $1.1 billion, reflecting the distinction between the value of equity and the operating business after net cash and debt.

The proposed acquisition remains subject to shareholder approval, court sanction and regulatory clearances. Silence expects closing in the first quarter of 2027. Calling the transaction a completed sale today would be premature, as would treating the full headline valuation as new capital being invested into UK laboratories.

What Merck is actually buying

Silence develops medicines based on small interfering RNA, or siRNA, designed to reduce production of particular proteins. Its leading candidate, divesiran, targets TMPRSS6 and is being developed for polycythaemia vera, a blood disorder in which the body produces too many red blood cells. Silence reported encouraging Phase 2 results and says the candidate has received US Fast Track and Orphan Drug designations.

A regulatory designation is not marketing approval, and clinical progress remains subject to larger trials and safety review. Merck's stated rationale is to add specialised therapies and capabilities to its pipeline, not to purchase a mature cash-generating product. The strategic asset is a programme and platform that might support future treatments.

A UK biotech exit with two interpretations

For investors, the transaction offers a cash exit at a substantial premium following a competitive sale process, according to Silence. It may also provide a drug developer with the capital, development infrastructure and commercial reach required for Phase 3 trials and eventual launch. Clinical-stage biotechnology is unusually capital-intensive and exposed to binary regulatory outcomes.

For Britain's life-sciences ecosystem, the same announcement raises a different question: can UK-origin research businesses remain independent through late-stage development, or will foreign acquirers frequently provide the most credible route to commercial scale? An acquisition is not automatically a loss of jobs or intellectual property. The answer depends on post-deal research investment, leadership and the location of future clinical and manufacturing work.

The acquisition is expected to use a scheme of arrangement under Part 26 of the UK Companies Act 2006. That process requires a court-supervised timetable and shareholder votes. Silence said holders representing about 14% of voting power had entered into support agreements. Those commitments reduce uncertainty but do not substitute for the required approvals.

The 130% premium also needs careful interpretation. It is calculated against one trading day's closing price, which can be depressed for a small clinical-stage company facing financing or development risk. The 82% premium against the 30-day volume-weighted average price provides a second reference, but neither figure independently proves the long-term value of the pipeline.

What to watch after the announcement

The next evidence points are the scheme circular, the shareholder meeting, regulatory review and any disclosed commitments on UK research operations. Investors will want to see whether clinical milestones are maintained during the transaction period and whether Merck changes the development timetable.

Silence's story is a reminder that British biotech success can be measured in several ways: scientific progress, access to capital, clinical outcomes and the domestic economic footprint left behind. The $1.3 billion price answers only one of those questions.